The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ACAA2 mRNA; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACAA2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ACHE mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of ACHE protein ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP3 protein]; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein] ACHE protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ACTR1A mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ACTR1A mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADCY7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ADCY7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADCY7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADGRL1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ADGRL1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ADNP mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ADNP mRNA]
amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AIF1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of AKR1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of AKR1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of AKR1A1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein]; bis(3)-cognitin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of AKT1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ALDH1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ALDH1A1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of APEX1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of APEX1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of API5 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of API5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ARF1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ARF3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ARF3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ASPM mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ASPM mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATP5B protein Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATP5B protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP6V0A4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0A4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V0C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V0C mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1B2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATP6V1B2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP6V1B2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ATP9A mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ATP9A mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ATRN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ATRN mRNA]
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAD protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BAP1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAP1 mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BAX protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]; mangiferin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BAX protein]
2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2 protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]; mangiferin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of BCL2L10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BCL2L10 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BDNF mRNA geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; MIR210 mRNA affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of BNIP3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of BNIP3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of C1R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of C1R mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CALM1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CALM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CALM1 mRNA]
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CASP1 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CASP1 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP1 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP12 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP12 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP3 protein; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP3 protein]; 6,7-dihydroxyflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of CASP3 protein]; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein]; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP3 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP9 protein; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of and results in increased activity of CASP9 protein]; [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CASP9 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 protein; ACHE protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP9 protein]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CASP9 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CASP9 mRNA]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CAT protein]; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased activity of CAT protein; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased activity of CAT protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CAT protein] Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of CAT protein]]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CBX5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CBX5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CBX5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CCL2 mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of CCL2 mRNA; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 mRNA]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNB1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCND2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCND2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNF mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CCNF mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNF mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CCNL2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCNL2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD151 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CD151 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CD44 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD44 mRNA]
(2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD68 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CD9 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CD9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDC42 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CDC42 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CDH11 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CDH11 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CDH11 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CETN3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CETN3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA CIB1 gene mutant form results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CIB1 mRNA; CIB1 gene mutant form promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of ASK1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CIB1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CKMT1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CKMT1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CKMT1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CLCA2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLCA2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CLSTN1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CLSTN1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CNN2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CNN2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CNR2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL1A1 mRNA] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COL1A1 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COL6A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of COL6A1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COQ8A mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COQ8A mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX5A protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7A2L mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of COX7A2L mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7A2L mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of COX7C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of COX7C mRNA]
CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein]; CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CST3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CST3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CST3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSB mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CTSL mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of CTSL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CTSL mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYC1 protein; geraniol inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYC1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of CYP11A1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP11A1 mRNA]
CYP2D6 protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Ketoconazole promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of CYP2D22 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DCXR mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DCXR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DCXR mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein] TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein] guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DLST protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DLST protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJA1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of DNAJB9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DNAJB9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DNAJB9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of DPP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DPP4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DPYSL2 protein Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of DPYSL2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ECM1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ECM1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ECM1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF1A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF1A1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EEF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EEF2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EFNA1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EFNA1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EFNB3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EFNB3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EFNB3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EGR1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EGR1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF2B4 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF2B4 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF4E mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EIF4E mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EIF5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EIF5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of EIF5 mRNA]
[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ENO1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO1 mRNA]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ENO2 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ENO2 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein] [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of ERP44 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ERP44 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERP44 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ETFA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ETFA mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of EZR mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of EZR mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of EZR mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of FBXL12 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FBXL12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FBXL12 mRNA]
FMC1 gene mutant form results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FMC1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FMC1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of FOSB protein; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of FOSB protein alternative form
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of FYN mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of FYN mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GAB1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GALE mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GALE mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GALE mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAP43 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GAPDH mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GAPDH mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GATA6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GATA6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GCLC mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GCLC mRNA]
[GDNF protein co-treated with Cyclic AMP] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GDNF protein
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GFAP protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Dieldrin promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GFAP protein]; zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GFAP protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GHITM mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GHITM mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GHITM mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GMFB mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GMFB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GNAI2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of GNAI2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GOLT1B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GOLT1B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPRC5C mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPRC5C mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GPX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GPX3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of GRID2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of GRID2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRID2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein (3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein] [mithramycin A co-treated with astaxanthine] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 mRNA]]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of GRIN1 protein]]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein]; bis(3)-cognitin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of GSK3B protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HBA-A1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HBA-A1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HELLS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HELLS mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine inhibits the reaction [Oxygen deficiency results in increased expression of HIF1A protein]; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A mRNA; [Clioquinol co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HIF1A protein [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite] affects the localization of HIF1A protein; [salicylaldehyde isonicotinoyl hydrazone co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine metabolite] affects the localization of HIF1A protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HINT1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HINT1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HIPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HIPK1 mRNA]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 mRNA; [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HMOX1 protein; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HMOX1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HNRNPC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HNRNPC mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HNRNPC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HNRNPC mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of HRAS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of HRAS mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of HSP90AA1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSP90AA1 mRNA]
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPE1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein]
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IDH3A protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL17A protein IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IGF1 protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL1A mRNA 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of IL1A mRNA guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL1A mRNA]
Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]] amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IL4RA mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of IL4RA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4RA mRNA]
IL6 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IL6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRAK1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IRAK1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of IRX3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of IRX3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ITM2B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ITM2B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of JMJD6 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of JMJD6 mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KAT6B mRNA; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KAT6B mRNA]
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KEAP1 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KEAP1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KIF3B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of KIF3B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]; Nicotine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of KIF3B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of KLF4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KLF4 mRNA]
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]; TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]; TIGAR protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of LPAR4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LPAR4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAOA mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAOA mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOA mRNA]
[MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of 1-Methyl-4-phenylpyridinium; [MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAOB protein]; Zonisamide inhibits the reaction [[MAOB protein results in increased metabolism of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased chemical synthesis of 1-Methyl-4-phenylpyridinium] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of MAOB protein 5-nitroindazole inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; 9-mono-N'-methylnorharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; Methylene Blue inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; norharman inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; Vitamin K 3 inhibits the reaction [MAOB protein results in increased oxidation of 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MAP2K7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP2K7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP2K7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP3K12 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAP3K12 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAP3K12 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of ASK1 protein CIB1 gene mutant form promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased phosphorylation of ASK1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK1 protein U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK1 protein] [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MAPK1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MAPK1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK3 protein U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased phosphorylation of MAPK3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MC2R mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MC2R mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MC2R mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of ME1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of ME1 mRNA]
MIR210 mRNA affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of BDNF protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR210 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MMP7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MMP7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MRPL10 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL10 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL20 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MRPL20 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MRPL9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MRPL9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MT2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MT3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of MTA1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTCH1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of MTCH1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTCH1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of MTF2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MTF2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NCAM1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NDUFB5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFB5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFB5 mRNA]
NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFS4 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NDUFS4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NDUFS4 mRNA]
NFE2L2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the expression of MIR380 mRNA]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR138-1 mRNA]; NFE2L2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of MIR674 mRNA]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NFE2L2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NGB mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NGB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS1 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NOS1 protein NOS1 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased ribosylation of Adenosine Diphosphate Ribose]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein] [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NOS2 protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NPL mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NPL mRNA]
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] affects the localization of and results in decreased expression of NR4A2 protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] affects the localization of and results in decreased expression of NR4A2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of NSF mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NSF mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of NSF mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NSF mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of NUPR1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of NUPR1 mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of OCLN protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of OCLN protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of OCLN protein
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of P3H3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of P3H3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of P3H3 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PAK2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PAK2 mRNA]
PARK7 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PARK7 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PARK7 mRNA]; PARK7 protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
[PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of 3,4-Dihydroxyphenylacetic Acid; [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Dopamine; [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Homovanillic Acid
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PDIA6 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PDIA6 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PDIA6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PFDN1 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PFDN1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHB mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PHTF1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PHTF1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PHTF1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIDD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIDD1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIGC mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIGC mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PIN1 mRNA; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIN1 mRNA]
PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 protein AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PINK1 protein]; PARK7 protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]; PRKN protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PIP5K1C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PIP5K1C mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PLAA mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PLAA mRNA]
PNOC affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; PNOC protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PNPLA8 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PNPLA8 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPARGC1A mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPARGC1A mRNA alternative form
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPM1B mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PPM1B mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PPM1B mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PPP2R3C mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PPP2R3C mRNA]
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRDX3 mRNA; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRDX3 mRNA]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRDX3 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PRKAB1 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKAB1 mRNA]
PRKN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH] AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN mRNA]; AM 1241 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN protein]; PRKN protein inhibits the reaction [PINK1 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] PRKN protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PRKN protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRKN mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PRKN protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMC5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of PSMC5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of PSMG2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PSMG2 mRNA]
guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein] CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PTGS2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of PYCARD mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PYCARD mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAB2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAB7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAB7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RAB7 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD1 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RAD50 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RAD50 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RAD50 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RASA3 mRNA; Caffeine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RASA3 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RBBP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA]; Nicotine promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RBBP4 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RBBP5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RBBP5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RBBP5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of RELA protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RGS2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RGS2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RGS2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL26 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of RPL26 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RPL5 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of RPL5 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RPL5 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of RSPO3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of RSPO3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SAP18 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SAP18 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SAP18 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SENP6 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SENP6 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SENP6 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SEPTIN7 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SEPTIN7 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SFPQ mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SFPQ mRNA]
[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC18A2 protein; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC18A2 protein]; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; Estrone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein] SLC18A2 protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC18A2 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of SLC1A1 protein Acetylcysteine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the localization of SLC1A1 protein]; Acetylcysteine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine affects the metabolism of SLC1A1 protein]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC2A1 protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC2A1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC40A1 protein 3,4-dihydroxybenzoate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC40A1 protein]
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein]; 2,3,5,4'-tetrahydroxystilbene 2-O-glucopyranoside inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of SLC6A3 protein; [Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC6A3 protein; Estradiol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC6A3 protein]; Estrone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased activity of SLC6A3 protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SLC6A3 protein]; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SLC6A3 protein]; vanoxerine inhibits the reaction [SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SLC6A3 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMAD1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMAD3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMAD3 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SMAD3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SMPD3 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SMPD3 mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SMPD3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein binds to SNCA protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB3A protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB5A protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [SNCA protein mutant form binds to RAB8A protein]; Dieldrin promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA protein U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SNCA protein alternative form; GPX1 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]; N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form]; U 0126 promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCA mRNA alternative form] SNCA affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; SNCA protein affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SNCG mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SNCG mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SOD2 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein [3,4-dihydroxybenzoate co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SOD2 protein; Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SOD2 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA SP1 affects the susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SP1 protein; [mithramycin A co-treated with astaxanthine] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of and affects the localization of SP1 protein]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]; astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]]; astaxanthine promotes the reaction [mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]; mithramycin A inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 mRNA]]; mithramycin A promotes the reaction [astaxanthine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SP1 protein]]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SRP9 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SRP9 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of STIP1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STIP1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STIP1 mRNA]
Levodopa inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of STMN1 protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of STX4A mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of STX4A mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of STX4A mRNA]
[Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of SYNGR2 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYNGR2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of SYT4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SYT4 mRNA] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of SYT4 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TFRC mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TFRC mRNA]
TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCL2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of CCR2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ICAM1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL4 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL6 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of KIT protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of PECAM1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of SLC6A3 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGFB1 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TGM2 protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of TGM2 protein
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(4-hydroxyphenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1,1-bis(3'-indolyl)-1-(p-anisyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein]; 1-(3-(2-(1-benzothiophen-5-yl) ethoxy) propyl)-3-azetidinol maleate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [[Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in decreased expression of TH protein; [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TH mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TH mRNA; [Nicotine co-treated with Polylactic Acid-Polyglycolic Acid Copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; [Zonisamide co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] affects the activity of TH protein; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; amentoflavone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; benserazide, levodopa drug combination inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; CSF3 protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; geraniol inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; ginkgetin inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Glyburide promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; juglone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Ketoconazole inhibits the reaction [Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA]; Telmisartan inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; Zonisamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TH protein PRKN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein
NADP inhibits the reaction [TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]]; TIGAR protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein]; TIGAR protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of LAMP1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIGAR protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIMP3 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TIMP3 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TIRAP mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TIRAP mRNA]
[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TJP1 protein; Trehalose inhibits the reaction [[Probenecid co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TJP1 protein] 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TJP1 protein
1,1-bis(3'-indolyl)-1-(4-chlorophenyl)methane inhibits the reaction [[1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TLR4 mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TLR4 mRNA
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein (2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid) trifluoroethylamide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine co-treated with Probenecid] results in increased expression of TNF mRNA; CNB 001 inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; Dimethyl Fumarate inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; IL17A protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; salvianolic acid B inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein] Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; guggulu extract inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; nimesulide inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF mRNA]; ropinirole inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]; ropinirole promotes the reaction [Ceftriaxone inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TNK2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TNK2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNK2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein [Nicotine co-treated with polylactic acid-polyglycolic acid copolymer] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRP53 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPH2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPH2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of TPP2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TPP2 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of TSC22D1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TSC22D1 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TUBA1A protein tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TUBA1A protein]
TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TH protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased cleavage of CASP12 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of DDIT3 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of ERN1 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of HSPA5 protein]; TXN protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TRAF2 protein] Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein] TXN protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN protein; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of TXN1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBB mRNA; Caffeine affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UBB mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UBC mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBC mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UBE2D2 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UBE2D2 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of UCHL1 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA] UCHL1 protein results in decreased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UCHL1 protein 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UCHL1 mRNA; 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of UCHL1 protein
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of UROS mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of UROS mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein TGM2 protein affects the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VCAM1 protein]
VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased activity of NOS2 protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of IL1B protein]; VIP protein inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of TNF protein]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS28 mRNA; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased expression of VPS28 mRNA]
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA [Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of VPS41 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of VPS41 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of VPS41 mRNA]
[Caffeine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in increased expression of WBP4 mRNA; [Nicotine co-treated with 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] results in decreased expression of WBP4 mRNA; Caffeine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA]; Nicotine inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in increased expression of WBP4 mRNA]
U 0126 inhibits the reaction [Arecoline results in increased expression of ACTA2 protein] Arecoline results in increased expression of ACTA2 mRNA; Arecoline results in increased expression of ACTA2 protein
[arecoline hydrobromide results in increased abundance of Arecoline] inhibits the reaction [2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester results in decreased phosphorylation of AKT1 protein]; [arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased phosphorylation of AKT1 protein; PHLPP2 protein affects the reaction [[arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased phosphorylation of AKT1 protein]
Arecoline results in increased expression of CCND1 mRNA; Arecoline results in increased expression of CCND1 protein [arecoline hydrobromide results in increased abundance of Arecoline] inhibits the reaction [2-amino-6-chloro-alpha-cyano-3-(ethoxycarbonyl)-4H-1-benzopyran-4-acetic acid ethyl ester results in decreased expression of CCND1 protein]; [arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased expression of CCND1 protein
[[Arecoline results in decreased expression of CDC25C] co-treated with [Arecoline results in increased expression of TP53]] results in decreased activity of CDK1 protein Arecoline results in decreased expression of CDC25C protein
Arecoline results in decreased activity of CDK1 protein [[Arecoline results in decreased expression of CDC25C] co-treated with [Arecoline results in increased expression of TP53]] results in decreased activity of CDK1 protein
Arecoline inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]; Arecoline inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA]
[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein; [helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of EGFR protein modified form; helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased phosphorylation of EGFR protein]
[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the expression of FOS protein; [helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the localization of FOS protein
[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK1 protein; Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK1 protein] Arecoline results in increased phosphorylation of MAPK1 protein U 0126 inhibits the reaction [Arecoline results in increased phosphorylation of MAPK1 protein]
[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK3 protein; Dinoprostone affects the reaction [[helioxanthin co-treated with Arecoline co-treated with 4-nitroquinolone-1-oxide] affects the phosphorylation of MAPK3 protein] U 0126 inhibits the reaction [Arecoline results in increased phosphorylation of MAPK3 protein]
[arecoline hydrobromide results in increased abundance of Arecoline] which results in increased expression of PHLPP2 mRNA; PHLPP2 protein affects the reaction [[arecoline hydrobromide results in increased abundance of Arecoline] which results in decreased phosphorylation of AKT1 protein]
Arecoline results in increased expression of PTGS2; Arecoline results in increased expression of PTGS2 mRNA [Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein; Dinoprostone inhibits the reaction [helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]]; helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [helioxanthin inhibits the reaction [[Arecoline co-treated with 4-nitroquinolone-1-oxide] results in increased expression of PTGS2 protein]]
[[Arecoline results in decreased expression of CDC25C] co-treated with [Arecoline results in increased expression of TP53]] results in decreased activity of CDK1 protein Arecoline results in increased expression of TP53 protein
CHRM1 gene results in increased susceptibility to xanomeline; CHRM1 results in increased susceptibility to xanomeline xanomeline binds to and results in increased activity of [CHRM1 protein binds to CHRM4 protein]
xanomeline binds to CHRM4 protein xanomeline binds to and results in increased activity of [CHRM1 protein binds to CHRM4 protein] [WIN 62577 co-treated with Quinuclidinyl Benzilate] inhibits the reaction [xanomeline binds to CHRM4 protein] CHRM4 gene results in increased susceptibility to xanomeline; CHRM4 results in increased susceptibility to xanomeline
browse the term
